Regulatory Story
Go to market news section View chart   Print
Company ABCAM Plc
TIDM ABC
Headline

Director/PDMR Shareholding

Released 13:10 30-Nov-2012
Number 4582S13

RNS Number : 4582S
ABCAM Plc
30 November 2012
 



For immediate release

30 November 2012

 

ABCAM PLC

("Abcam" or "the Company")

PDMR dealing

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, announces that following completion of three years of continued employment since the award of Matching Shares under the Share Incentive Plan, the risk of forfeiture attached to these shares has now been removed, resulting in an increase in the beneficial holding of the following PDMRs:

Name

Matching Shares now transferred to beneficial ownership

Date of transfer to beneficial ownership

Total subsequent beneficial holding

Percentage of share capital

Mark Bushfield

65

30 November 2012

3,475

0.003%

Philippe Cotrel

65

30 November 2012

9,442

0.005%

 

For further information please contact:

Abcam

+ 44 (0) 1223 696 000

Jeff Iliffe, Chief Financial Officer

 


Numis Securities - Nominated Adviser & Joint Broker

+ 44 (0) 20 7260 1000

Michael Meade - Nominated Adviser


James Black - Corporate Broking

 


Peel Hunt LLP - Joint Broker

+ 44 (0) 20 7418 8900

Andy Crossley - Corporate Broking

 


Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles


 

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.

Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan), Hangzhou and Hong Kong (both in China), allowing it to serve a global customer base in over 130 countries. Abcam employs over 600 staff across its eight operating companies.

Abcam now has an online catalogue of over 100,000 products sourced from over 400 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.

Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the world's leading life science tools company.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSXBLFXLFFBFBK
Close


London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

 


Director/PDMR Shareholding - RNS